The tumour vanishes.
Todd
J F
JF
Endocrine Unit, Hammersmith Hospital, Imperial College of Science, Technology and Medicine, London, UK.
Meeran
K
K
D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007078:Ileal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D015282:Octreotide / Q000378:metabolism / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide